[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452259":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":84,"collaborators":86,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":7,"enrollmentInfo":107,"targetDuration":7,"studyType":110,"phases":7,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"University of Sydney","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Paul Keall, PhD","STUDY_CHAIR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Shona Silvester","CONTACT","+61 2 8627 1185","Shona.Silvester@sydney.edu.au",[19,37,49,63,76],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Calvary Mater Newcastle Hospital","NOT_YET_RECRUITING","Waratah","New South Wales","2298","Australia","AU",{"type":28,"coordinates":29},"Point",[30,31],151.72647,-32.90667,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":7,"phoneExt":7,"email":36},"Principal Investigator","Jarad.Martin@calvarymater.org.au",{"facility":38,"status":21,"city":39,"state":23,"zip":40,"country":25,"countryCode":26,"cosmosGeoPoint":41,"geoPoint":45,"contacts":46},"Westmead Hospital","Westmead","2145",{"type":28,"coordinates":42},[43,44],150.98768,-33.80383,{"lat":44,"lon":43},[47],{"name":35,"role":15,"phone":7,"phoneExt":7,"email":48},"Tim.Wang2@health.nsw.gov.au",{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":25,"countryCode":26,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Princess Alexandra Hospital","RECRUITING","Woolloongabba","Queensland","4102",{"type":28,"coordinates":56},[57,58],153.03655,-27.48855,{"lat":58,"lon":57},[61],{"name":35,"role":15,"phone":7,"phoneExt":7,"email":62},"David.Pryor@health.qld.gov.au",{"facility":64,"status":21,"city":65,"state":66,"zip":67,"country":25,"countryCode":26,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000",{"type":28,"coordinates":69},[70,71],144.96332,-37.814,{"lat":71,"lon":70},[74],{"name":35,"role":15,"phone":7,"phoneExt":7,"email":75},"Richard.Khor@austin.org.au",{"facility":77,"status":21,"city":65,"state":66,"zip":67,"country":25,"countryCode":26,"cosmosGeoPoint":78,"geoPoint":80,"contacts":81},"The Austin Hospital",{"type":28,"coordinates":79},[70,71],{"lat":71,"lon":70},[82],{"name":35,"role":15,"phone":7,"phoneExt":7,"email":83},"Nick.Hardcastle@petermac.org",{"type":85,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[87,89,91,94,96],{"name":88,"class":6},"Calvary Mater Newcastle, Australia",{"name":90,"class":6},"Western Sydney Local Health District",{"name":92,"class":93},"Austin Health","OTHER_GOV",{"name":95,"class":6},"Peter MacCallum Cancer Centre, Australia",{"name":97,"class":6},"Princess Alexandra Hospital, Brisbane, Australia","100452259","radio-opaque-contrast-agents-for-liver-cancer-targeting-with-kim-during-radiation-therapy-100452259",false,"NCT05169177","Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy","ROCK-RT","Inclusion Criteria:\n\n* Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.\n* Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan\n* The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.\n* Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Minimum image dataset is not available\n* Image dataset is not in a compatible format","ALL","18 Years",{"count":108,"type":109},50,"ESTIMATED","OBSERVATIONAL","This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).",[113],"Liver Neoplasm",[115,116,117,118,119],"Radiation Therapy","Stereotactic Ablative Body Radiation Therapy","SABR","Kilovoltage intrafraction monitoring","Radio opaque contrast","2026-05-15",{"date":122,"type":123},"2026-05-19","ACTUAL",{"date":125,"type":123},"2022-10-17",{"date":127,"type":109},"2026-10-31",{"name":5,"class":6},5]